非アルコール性脂肪性肝炎市場 - 2031年の成長予測、統計および事実

  • Report Code : TIPRE00009653
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 178
Buy Now

非アルコール性脂肪性肝炎 (NASH) 市場は、2021 年の 16 億 3,192 万ドルから 2028 年までに 242 億 6,681 万ドルに達すると予測されています。 2021 年から 2028 年にかけて 47.1% の CAGR を記録すると予想されます。



非アルコール性脂肪肝疾患 (NAFLD) では、肝臓に脂肪が蓄積します。非アルコール性脂肪肝 (NAFL) と非アルコール性脂肪性肝炎 (NASH) は、NAFLD の一種です。脂肪の蓄積が炎症や損傷を引き起こすと、NASH の発症につながり、肝臓の瘢痕化につながる可能性があります。肝臓の瘢痕化は、肝硬変と呼ばれる生命を脅かす可能性のある状態です。



このレポートは、非アルコール性脂肪性肝炎 (NASH) 市場の洞察と詳細な分析を提供し、市場動向、技術の進歩、市場力学などのさまざまなパラメーターを強調しています。また、世界中の主要な市場プレーヤーの競争状況分析も提供します。さらに、COVID-19 パンデミックがすべての地域の市場に与える影響も含まれています。 COVID-19 パンデミックは、世界中のさまざまな国の社会経済状況を混乱させています。北米では、米国が COVID-19 パンデミックの影響を大きく受けました。 COVID-19 患者におけるトランスアミナーゼの増加と高ビリルビン血症という形での肝障害は、既存の肝疾患を含むいくつかの要因に起因する可能性があります。これらの患者における非アルコール性脂肪性肝疾患 (NAFLD) と NASH の併存症により、重度の肝障害を起こしやすくなります。世界中でNAFLDの有病率が高いことを考えると、併存疾患、疾患の進行、COVIDの重症度の役割を含む、そのような患者におけるCOVID-19の結果を認識することは非常に重要です. NASH/NAFLD ではなく線維症の存在は、COVID-19 患者の臨床転帰の悪化と死亡率の上昇に関連しています。



人を含む併存患者集団に対する COVID-19 の影響糖尿病、肥満、脂肪肝疾患、および NASH を伴う疾患は、患者に最適なケアを提供する必要性を引き起こしています。 Global Liver Institute は、世界中の研究者やイノベーターと協力して、このパンデミックに対する強力な対応を迅速に評価し、情報を提供することに取り組んでいます。 NAFLDおよびNASHとの闘いを中心に展開する研究は、体重の問題との予想される関係が厳しいことを示しています.したがって、NASH の発生率が高いと高度な診断と治療が必要になり、市場での研究開発が促進されます。このように、COVID-19 の危機は、非アルコール性脂肪性肝炎 (NASH) 市場の成長に拍車をかけています。



戦略的洞察



有利な地域非アルコール性脂肪性肝炎 (NASH) 市場向け



市場の洞察



NASH の認識を高めるためのイニシアチブの増加が市場の成長を促進



NASH は十分に認識されていない状態です。構造化された紹介経路と早期発見のためには、一般大衆とプライマリケア医 (PCP) の間でこの病気の認識を高めることが不可欠です。紹介と患者意識向上キャンペーンのための明確な患者経路を確立することにより、より多くの個人を特定し、さらなる評価のために専門家に送ることができます。 NASH の意識を高めるために、NASH 教育プログラムは、2018 年 6 月 12 日に「国際 NASH デー」として、NAFLD とそのより高度な形態である NASH についての意識を高めるための一般教育キャンペーンを開始しました。



NASH 24X7 は、NASH の流行に関する露出と認識を高めることを目的としたデジタル プラットフォームであり、2019 年の国際 NASH デーにおいて、HCP のサポート、患者の意識向上、およびプレス/テレビ リリース プログラム。この日の意識を高めるために、NASH 24X7 の NASH Crusaders は、インド全土のトップ ヘルスケア プロバイダー (HCP)、特に消化器内科医や肝臓専門医と協力して、肝臓の健康に関する小規模および大規模な意識向上と教育のワークショップを多数開催し、健康管理の必要性を強調しました。 NAFLD/NASH の予防におけるライフスタイル。



2020 年の国際 NASH デーに、American Liver Foundation はグローバル コミュニティに参加し、アラガン財団の支援を受けて NASH に関する意識を高めました。 American Liver Foundation (ALF) は現在、NASH テキスト メッセージ プログラムを試験運用しています。このプログラムにサインアップすると、毎週 3 つのメッセージを 10 週間受け取ることができます。メッセージは、NASH リソースへのハイパーリンク、関連する事実、インタラクティブなクイズ、および日常の自己管理のための実用的なポインターで構成されています。 ALF は、パイロットが終了して評価された時点で、このシステムを一般に公開します。国際 NASH デーに Global Liver Institute (GLI) と協力し、GLI の投稿と国際 NASH デーのページにリンクされたソーシャル メディアの投稿をいくつか共有しました。



したがって、 NASH に関する認識を促進するためのイニシアチブは、非アルコール性脂肪性肝炎 (NASH) 市場を牽引しています。



製品ベースの洞察



製品に基づいて、非アルコール性脂肪性肝炎 (NASH) 市場は、ビタミン E とピオグリタゾン、オカリバ、エラフィブラノール、セロンセルチブとセニクリビロックなどに分割されます。 2021年には、その他のセグメントが市場で最大のシェアを占めました。セロンセルチブとセニクリビロックのセグメントは、予測期間中に 73.3% という最速の CAGR を記録すると予想されます。



臓器保存ソリューション市場、製品別 - 2020 年および 2028 年



アプリケーションベースの洞察


アプリケーションに基づいて、非アルコール性脂肪性肝炎 (NASH) 市場は治療と診断に分かれています。 2021年には、治療セグメントが市場でより大きなシェアを占めました。ただし、治療セグメントは、予測期間中に 47.3% という高い CAGR を記録すると予想されます。



販売チャネル ベースのインサイト



販売チャネルに基づいて、非アルコール性脂肪性肝炎 (NASH) 市場は、病院薬局、小売薬局、およびオンライン プロバイダーに分割されます。 2021 年には、小売薬局セグメントが市場で最大のシェアを占めました。さらに、小売薬局セグメントは、2021 年から 2028 年の間に 47.2% という最高の CAGR を報告すると予想されます。



非アルコール性脂肪性肝炎 (NASH) 市場のプレーヤーは、製品などの有機的な戦略を採用しています。



By



地域< /h3>

地理に基づいて、非アルコール性脂肪性肝炎 (NASH) 市場は、北米 (米国、カナダ、メキシコ)、ヨーロッパ (英国、ドイツ、フランス、イタリア、スペイン) に分割されます。 、およびその他のヨーロッパ)、アジア太平洋 (中国、日本、インド、オーストラリア、韓国、およびアジア太平洋のその他の地域)、中東およびアフリカ (UAE、サウジアラビア、南アフリカ、および中東およびアフリカのその他の地域) 、中南米 (ブラジル、アルゼンチン、中南米のその他の地域)。



会社概要




  1. Genfit SA

  2. One Way Liver, SL

  3. BioPredictive SAS

  4. Cadila Pharmaceuticals Ltd.

  5. Prometheus Laboratories

  6. Siemens Healthineers AG

  7. Intercept Pharmaceuticals, Inc.

  8. Novartis AG

  9. Galmed Pharmaceuticals

  10. Laboratory Corporation of America Holdings



Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is non-alcoholic steatohepatitis (NASH)?

Nonalcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in your liver. Nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) are types of NAFLD. Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.

What are the driving factors for the non-alcoholic steatohepatitis (NASH) market across the globe?

Key factors that are driving the growth of this market are the rising prevalence of NASH and increasing initiatives for the awareness of NASH. Additionally, the growing clinical trials involving combination studies of drugs is likely to emerge as a significant future trend in the market during the forecast period.

What is the market CAGR value of the non-alcoholic steatohepatitis (NASH) market during the forecast period?

The CAGR value of the non-alcoholic steatohepatitis (NASH) market during the forecasted period of 2021–2028 is 47.1%.

Which product led the non-alcoholic steatohepatitis (NASH) market?

The product segment of the non-alcoholic steatohepatitis (NASH) market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market, by product. The selonsertib & cenicriviroc segment of the non-alcoholic steatohepatitis (NASH) market is expected to witness growth in its demand at the fastest CAGR of 73.3% from 2024 to 2028.

Which application held the largest share in the non-alcoholic steatohepatitis (NASH) market?

The treatment segment dominated the global non-alcoholic steatohepatitis (NASH) market and accounted for the largest market share of 84.90% in 2021.

Which sales channel held the largest share in the non-alcoholic steatohepatitis (NASH) market?

The retail pharmacy segment dominated the global non-alcoholic steatohepatitis (NASH) market and accounted for the largest market share of 61.39% in 2021.

Who are the key players in the non-alcoholic steatohepatitis (NASH) market?

The non-alcoholic steatohepatitis (NASH) market majorly consists of players such as Genfit SA; One Way Liver, S.L.; BioPredictive S.A.S.; Cadila Pharmaceuticals Ltd.; Prometheus Laboratories; Siemens Healthineers AG; Intercept Pharmaceuticals, Inc.; Novartis AG; Galmed Pharmaceuticals; and Laboratory Corporation of America Holdings amongst others.

Which are the top companies that hold the market share in non-alcoholic steatohepatitis (NASH) market?

Intercept Pharmaceuticals, Inc and Genfit SA are the top two companies that hold huge market shares in the non-alcoholic steatohepatitis (NASH) market.

Which region is expected to witness significant demand for the non-alcoholic steatohepatitis (NASH) market in the coming years?

North America held the largest market share for non-alcoholic steatohepatitis in 2021. The United States held the largest market in North America for non-alcoholic steatohepatitis, and the market is expected to grow due to increasing adoption of technological advancements and rising emphasis on improving treatment outcomes are projected to accelerate the growth of the non-alcoholic steatohepatitis market.

What is the COVID 19 impact on the non-alcoholic steatohepatitis (NASH) market in the coming years?

The presence of nonalcoholic fatty liver disease (NAFLD) and NASH in patients with COVID-19 is likely to cause them to be prone to severe forms of liver injury. Given the high prevalence of NAFLD worldwide, it's far critical to recognize the results of COVID-19 in such patients, which include the role of comorbidities, disease progression, and the severity of COVID-19. The presence of fibrosis rather than NASH/NAFLD is associated with worse clinical outcomes and higher mortality in COVID-19 patients. Additionally, there seems to be an increased likelihood of liver injury in NAFLD patients with COVID-19.
NASH had the strongest association with COVID-19 of all comorbid metabolic conditions, including hypertension and obesity. As the world keeps confronting the novel coronavirus pandemic, the impact of COVID-19 on specific patient populations, which includes people with diabetes, obesity, fatty liver disease, and NASH, has proven the need of providing actionable recommendations to clinicians and patients to offer optimal care and avoid needless deaths. The Global Liver Institute is committed to operating with researchers and innovators worldwide to evaluate and inform a strong response to this pandemic rapidly. As the push to combat NAFLD and NASH continues, research indicates that the anticipated relationship with weight problems is stark. Individuals with signs and symptoms of underlying fatty liver disease and NASH are at higher risk and infectious for longer for COVID-19. Therefore, COVID-19 is affected positively on the growth of the market.

The List of Companies - Non-Alcoholic Steatohepatitis (NASH) Market
  1. Genfit SA
  2. One Way Liver, S.L.
  3. BioPredictive S.A.S
  4. Cadila Pharmaceuticals Ltd.
  5. Prometheus Laboratories
  6. Siemens Healthineers AG
  7. Intercept Pharmaceuticals, Inc.
  8. Novartis AG
  9. Galmed Pharmaceuticals
  10. Laboratory Corporation of America Holdings

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports